Immune Checkpoint Inhibitors and Other Immune Therapies in Breast Cancer: A New Paradigm for Prolonged Adjuvant Immunotherapy

Abstract

Breast cancer is the most common form of cancer in women worldwide. Advances in the early diagnosis and treatment of cancer in the last decade have progressively decreased the cancer mortality rate, and in recent years, immunotherapy has emerged as a relevant tool against cancer. HER2+ and triple-negative breast cancers (TNBCs) are considered more immunogenic and suitable for this kind of treatment due to the higher rate of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression. In TNBC, genetic aberrations further favor immunogenicity due to more neo-antigens in cancer cells. Methods: This review summarizes the principal ongoing conventional and investigational immunotherapies in breast cancer. Particularly, immune checkpoint inhibitors (ICIs) and their use alone or combined with DNA damage repair inhibitors (DDRis) are described. Then, the issue on immunotherapy with monoclonal antibodies against HER-2 family receptors is updated. Other investigational immunotherapies include a new schedule based on the interferon beta-interleukin-2 sequence that was given in ER+ metastatic breast cancer patients concomitant with anti-estrogen therapy, which surprisingly showed promising results. Results: Based on the scientific literature and our own findings, the current evaluation of tumor immunogenicity and the conventional model of adjuvant chemotherapy (CT) are questioned. Conclusion: A novel strategy based on additional prolonged adjuvant immunotherapy combined with hormone therapy or alternated with CT is proposed.

POLD4 Promotes Glioma Cell Proliferation and Suppressive Immune Microenvironment: A Pan-Cancer Analysis Integrated with Experimental Validation

“…Immunotherapies have made remarkable strides in the field of immune checkpoint therapy [ 15 ]. Therefore, we further investigated the correlation between POLD4 expression and the key factors influencing the effectiveness of immunotherapy, including immune checkpoints, immunosuppressive genes, chemokine receptors, chemokines, and MHC gene expression, spanning a comprehensive range of 33 different cancer types.…”

A novel tumor-associated neutrophil gene signature for predicting prognosis, tumor immune microenvironment, and therapeutic response in breast cancer

“…The most common biomarkers of immune checkpoint inhibitors, PD-1, CTLA-4, and CD28 receptors, are present on activated effector T cells that interact with members of their ligand B7 family: B7-1 (CD80), B7-2 (CD-86), or CD274 (PD-L1) 31 . We can use this feature to stratify BRCA patients receiving immunotherapy.…”

Molecular profiling of metastatic breast cancer and target-based therapeutic matching in an Asian tertiary phase I oncology unit

“…In the treatment-refractory setting, pembrolizumab has agnostic approval in the presence of dMMR/MSI-H or TMB ≥ 10 mt/Mb ( 8 , 9 ). Numerous ongoing studies continue to evaluate the application of ICI in MBC while attempting to derive an optimal biomarker ( 32 ).…”